GeneDx (NASDAQ:WGS) and SBC Medical Group (NASDAQ:SBC) Head to Head Review

GeneDx (NASDAQ:WGS) and SBC Medical Group (NASDAQ:SBC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, valuation and profitability.

Earnings and Valuation

This table compares GeneDx and SBC Medical Group”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeneDx	$427.54 million	2.70	-$21.02 million	($2.68)	-14.50
SBC Medical Group	$173.61 million	1.76	$50.99 million	$0.49	6.08

SBC Medical Group has lower revenue, but higher earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than SBC Medical Group, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares GeneDx and SBC Medical Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GeneDx	-17.58%	9.15%	5.21%
SBC Medical Group	29.37%	20.76%	15.67%

Analyst Ratings

This is a summary of recent ratings and recommmendations for GeneDx and SBC Medical Group, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeneDx	1	1	6	0	2.63
SBC Medical Group	0	1	2	0	2.67

GeneDx currently has a consensus price target of $96.43, indicating a potential upside of 148.21%. SBC Medical Group has a consensus price target of $8.50, indicating a potential upside of 185.23%. Given SBC Medical Group’s stronger consensus rating and higher possible upside, analysts plainly believe SBC Medical Group is more favorable than GeneDx.

Insider & Institutional Ownership

61.7% of GeneDx shares are held by institutional investors. Comparatively, 60.8% of SBC Medical Group shares are held by institutional investors. 29.6% of GeneDx shares are held by company insiders. Comparatively, 89.5% of SBC Medical Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

GeneDx has a beta of 2.06, suggesting that its share price is 106% more volatile than the S&P 500. Comparatively, SBC Medical Group has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500.

Summary

SBC Medical Group beats GeneDx on 9 of the 14 factors compared between the two stocks.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.

About SBC Medical Group

SBC Medical Group Holdings Incorporated, through its subsidiaries, provides services to support the operation of clinics which deliver specialized medical services in the areas of cosmetic medicine, esthetic dentistry and Androgenetic Alopecia or AGA, primarily in Japan and centered on the SBC Shonan Beauty Clinic Brand. SBC Medical Group Holdings Incorporated, formerly known as Pono Capital Two Inc., is based in TOKYO.